|
Exploring New Frontiers in Cancer Treatment: The Expanded Role of Cellular Therapies |
1.00 |
06/30/2025 - 12:00am to 03/01/2026 - 12:00am |
|
NCCN Guidelines® Insights - Thyroid Carcinoma, Version 1.2025 |
1.00 |
07/10/2025 - 12:00am to 07/10/2026 - 12:00am |
|
NCCN Tumor Boards: New and Emerging Systemic Therapy Options in Bladder Cancer |
1.00 |
07/11/2025 - 12:00am to 11/01/2025 - 12:00am |
|
Optimizing Patient Outcomes - The Role of Immunotherapy and Emerging Strategies for High-Risk Neuroblastoma |
1.00 |
07/29/2025 - 12:00am to 01/11/2026 - 12:00am |
|
Recorded Presentation from Optimizing Patient Outcomes - Understanding the Mismatch Repair Deficient (dMMR)/Microsatellite-High (MSI-H) Treatment... |
1.00 |
07/29/2025 - 12:00am to 07/23/2026 - 12:00am |
|
NCCN Tumor Boards - Optimal Treatment Strategies for Metastatic Breast Cancer |
1.00 |
07/31/2025 - 12:00am to 01/25/2026 - 12:00am |
|
NCCN Guidelines® Insights - Uterine Neoplasms, Version 3.2025 |
1.00 |
08/10/2025 - 12:00am to 08/10/2026 - 12:00am |
|
Archived NCCN Tumor Boards: Skin Cancers Except Melanoma - Radiation Therapy Treatment Options |
1.00 |
08/13/2025 - 12:00am to 07/31/2026 - 11:59pm |
|
Recorded Presentation from Optimizing Patient Outcomes - New Primary Therapy Options for Stage III-IV Hodgkin Lymphoma |
1.00 |
08/25/2025 - 12:00am to 08/13/2026 - 11:59pm |
|
Archived NCCN Tumor Boards: New and Emerging Systemic Therapy Options in Bladder Cancer |
1.00 |
09/05/2025 - 12:00am to 08/24/2026 - 11:59pm |
|
NCCN Guidelines® Insights - Non–Small Cell Lung Cancer, Version 7.2025 |
1.00 |
09/10/2025 - 12:00am to 09/10/2026 - 12:00am |
|
Optimizing Patient Outcomes - The Changing Treatment Paradigm for Mantle Cell Lymphoma: Improving the Prognosis with Targeted Inhibitors and Evolving... |
1.00 |
09/12/2025 - 12:00am to 03/15/2026 - 12:00am |
|
NCCN 2025 Annual Congress: Hematologic Malignancies™ |
14.50 |
10/11/2025 - 12:45pm to 01/31/2026 - 11:59pm |
Facebook
X
LinkedIn
Forward